Ambu A/S
CSE:AMBU B

Watchlist Manager
Ambu A/S Logo
Ambu A/S
CSE:AMBU B
Watchlist
Price: 106.15 DKK -0.14%
Market Cap: 28.3B DKK
Have any thoughts about
Ambu A/S?
Write Note

Ambu A/S
Total Liabilities & Equity

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Ambu A/S
Total Liabilities & Equity Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Total Liabilities & Equity CAGR 3Y CAGR 5Y CAGR 10Y
Ambu A/S
CSE:AMBU B
Total Liabilities & Equity
kr7.2B
CAGR 3-Years
8%
CAGR 5-Years
9%
CAGR 10-Years
N/A
GN Store Nord A/S
CSE:GN
Total Liabilities & Equity
kr29.6B
CAGR 3-Years
19%
CAGR 5-Years
15%
CAGR 10-Years
12%
Demant A/S
CSE:DEMANT
Total Liabilities & Equity
kr32.4B
CAGR 3-Years
11%
CAGR 5-Years
9%
CAGR 10-Years
12%
V
ViroGates A/S
CSE:VIRO
Total Liabilities & Equity
kr14.1m
CAGR 3-Years
-15%
CAGR 5-Years
-23%
CAGR 10-Years
N/A
No Stocks Found

Ambu A/S
Glance View

Market Cap
28.3B DKK
Industry
Health Care

Ambu A/S, a Danish company rooted in innovation, has carved a niche in the global healthcare sector through its specialized medical devices. Founded in 1937, Ambu started with a simple mission of improving patient care and has stayed true to that vision by continuously advancing their portfolio. The company's journey began with the invention of the resuscitator bag, a revolutionary product that remains a staple in emergency and hospital settings today. Over the years, Ambu has focused strategically on three main segments: Anesthesia, Patient Monitoring & Diagnostics, and Visualisation, each playing a crucial role in the broader healthcare ecosystem. These segments allow Ambu to develop devices that enhance diagnostic procedures, improve safety, and increase efficiency in medical settings, ultimately saving lives and optimizing healthcare delivery. Ambu’s business model capitalizes primarily on innovation-driven sales, with a strong emphasis on disposable medical devices which are gaining popularity due to hygiene concerns and regulatory trends favoring single-use technologies. These products include their flagship single-use endoscopes, marketed under the brand name "Ambu aScope," which significantly reduce the risk of cross-contamination while providing high-quality diagnostic images. The company's revenue model is built on a B2B approach, dealing directly with hospitals, clinics, and other healthcare providers, ensuring a steady flow of sales through long-term contracts and partnerships. Through constant reinvestment into R&D and strategic acquisitions, Ambu sustains its market leadership, driving growth by addressing the evolving needs of the healthcare industry and setting standards in patient care solutions globally.

AMBU B Intrinsic Value
98.82 DKK
Overvaluation 7%
Intrinsic Value
Price

See Also

What is Ambu A/S's Total Liabilities & Equity?
Total Liabilities & Equity
7.2B DKK

Based on the financial report for Sep 30, 2024, Ambu A/S's Total Liabilities & Equity amounts to 7.2B DKK.

What is Ambu A/S's Total Liabilities & Equity growth rate?
Total Liabilities & Equity CAGR 5Y
9%

Over the last year, the Total Liabilities & Equity growth was 4%. The average annual Total Liabilities & Equity growth rates for Ambu A/S have been 8% over the past three years , 9% over the past five years .

Back to Top